Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that increased uptake of expensive maintenance therapies, including drugs from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Pfizer, will help drive robust 9% annual growth in the market to treat chronic obstructive pulmonary disease (COPD).

The new Pharmacor report entitled Chronic Obstructive Pulmonary Disease finds that increased uptake of Boehringer Ingelheim/Pfizer's Spiriva (tiotropium), GlaxoSmithKline's Advair/Seretide (fluticasone/salmeterol), and AstraZeneca's Symbicort (budesonide/formoterol), will be driven by a growing acceptance in Europe of these expensive and more effective drugs. The increased uptake will also be driven by earlier maintenance treatment in the United States and United Kingdom and increased prescribing of multiple long- acting bronchodilators for greater symptom control.

The report also finds that although the market will more than double from 2004 to 2014, significant commercial potential for COPD treatments remains largely untapped.

"Aging population demographics and improvements in diagnostic practices for COPD, which is currently significantly under-diagnosed in the United States, Western Europe, and Japan, will expand the COPD drug-treated population through 2014," said Cindy Mundy, Ph.D., analyst at Decision Resources, Inc. "Despite the size and potential of this market, huge opportunity exists for drug developers because the COPD pipeline is small and lacks any truly innovative approaches to address the most pressing unmet needs in this indication -- a disease-modifying pharmacotherapy and an effective anti-inflammatory agent."

About Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease is the fourth-leading cause of chronic morbidity and mortality in the United States and is projected to rank fifth in the global disease burden in 2020 by the World Health Organization.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, alloc2ate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Maryland Lightens Health Insurance on Small Businesses, According to HealthLeaders-InterStudy

View Now